SX
60 Degrees Pharmaceuticals, Inc.
SXTP · NASDAQ
$0.96 -3.41% (-$0.03)
1M -15.40%
Market Cap $800.6K
P/E Ratio -
Div. Yield -
ROE 212.78%
Bulios Fair Price
$1.03
7.7% upside
Current Price
$0.96
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SXTP is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.32x
P/S 0.72x
EV/FFO N/A
Growth
100 /100
Growing Rev. growth 65.15%
Book val. growth N/A
EPS growth N/A
Profitability
6 /100
Weak Op. margin 774.90%
Gross margin 19.42%
FCF margin 355.27%
Quality
3 /100
Poor ROA 189.43%
ROIC 352.37%
Asset turnover 0.26x
Debt
69 /100
Low Int. coverage -1,069.34x
Debt/Equity 0.00x
Current ratio 2.32x
Stability
1 /100
Unstable EPS volatility 1,097.77%
Beta 2.54x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SXTP
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Geoffrey Stuart Dow
Employees
3
Headquarters
Washington
Upcoming events
12 NOV
Earnings
Upcoming earnings report